|
1 Indications And Usage Brilinta Is A P2y12 Platelet Inhibitor Indicated • To Reduce The Risk Of Cardiovascular (Cv) Death, Myocardial Infarction (Mi), And Stroke In Patients With Acute Coronary Syndrome (Acs) Or A History Of Mi. For At Least The First 12 Months Following Acs, It Is Superior To Clopidogrel. Brilinta Also Reduces The Risk Of Stent Thrombosis In Patients Who Have Been Stented For Treatment Of Acs. ( 1.1 ) • To Reduce The Risk Of A First Mi Or Stroke In Patients With Coronary Artery Disease (Cad) At High Risk For Such Events. While Use Is Not Limited To This Setting, The Efficacy Of Brilinta Was Established In A Population With Type 2 Diabetes Mellitus (T2dm). ( 1.2 ) 1.1 Acute Coronary Syndrome Or A History Of Myocardial Infarction Brilinta Is Indicated To Reduce The Risk Of Cardiovascular Death, Myocardial Infarction (Mi), And Stroke In Patients With Acute Coronary Syndrome (Acs) Or A History Of Mi. For At Least The First 12 Months Following Acs, It Is Superior To Clopidogrel. Brilinta Also Reduces The Risk Of Stent Thrombosis In Patients Who Have Been Stented For Treatment Of Acs [See Clinical Studies (14.1) ] . 1.2 Coronary Artery Disease But No Prior Stroke Or Myocardial Infarction Brilinta Is Indicated To Reduce The Risk Of A First Mi Or Stroke In Patients With Coronary Artery Disease (Cad) At High Risk For Such Events [See Clinical Studies (14.2) ] . While Use Is Not Limited To This Setting, The Efficacy Of Brilinta Was Established In A Population With Type 2 Diabetes Mellitus (T2dm).
|